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ttp://dx.doi.org/10.1016/j.ajpath.2013.06.026Glioblastoma is a highly vascularized brain tumor, and antiangiogenic therapy improves its progression-
free survival. However, current antiangiogenic therapy induces serious adverse effects including
neuronal cytotoxicity and tumor invasiveness and resistance to therapy. Although it has been suggested
that the physical microenvironment has a key role in tumor angiogenesis and progression, the mech-
anism by which physical properties of extracellular matrix control tumor angiogenesis and glioblastoma
progression is not completely understood. Herein we show that physical compaction (the process in
which cells gather and pack together and cause associated changes in cell shape and size) of human
glioblastoma cell lines U87MG, U251, and LN229 induces expression of collagen types IV and VI and the
collagen crosslinking enzyme lysyl oxidase and up-regulates in vitro expression of the angiogenic factor
vascular endothelial growth factor. The lysyl oxidase inhibitor b-aminopropionitrile disrupts collagen
structure in the tumor and inhibits tumor angiogenesis and glioblastoma multiforme growth in a mouse
orthotopic brain tumor model. Similarly, D-penicillamine, which inhibits lysyl oxidase enzymatic activity
by depleting intracerebral copper, also exhibits antiangiogenic effects on brain tumor growth in mice.
These ﬁndings suggest that tumor microenvironment controlled by collagen structure is important in
tumor angiogenesis and brain tumor progression. (Am J Pathol 2013, 183: 1293e1305; http://
dx.doi.org/10.1016/j.ajpath.2013.06.026)Supported by funds from the American Heart Association (A.M.),
a William Randolph Hearst Award (A.M.), the American Brain Tumor
Association (A.M.), a Children’s Hospital Boston Faculty Career Devel-
opment Fellowship (T.M.), the Stop and Shop Pediatric Brain Tumor Fund
(M.W.K.), the C.J. Buckley Pediatric Brain Tumor Fund (M.W.K), grant
R01 CA148633 from the National Cancer Institute, NIH (D.P.), and grant
W81XWH-05-1-0115 from Department of Defense.
T.M. and A.M. contributed equally to this work.Glioblastoma multiforme (GBM), a highly malignant glioma
that exhibits various glial lineages such as a mixed oligoden-
droglialeastrocytic phenotype,1 is the most common primary
brain tumor. Every year in the United States, GBM is diag-
nosed in about 8000 persons. Despite a great deal of effort
to develop effective therapies targeting GBM, current
approaches including surgery, radiotherapy, and chemo-
therapy have not been successful, withmedian survival of only
1 to 2 years.2 Angiogenesis, the formation and development of
new blood vessels, is an important step in tumor growth and
metastasis.3,4 Since GBM is a highly vascularized tumor and
the presence of neovascularization is a key diagnostic criteria
for GBM, antiangiogenic therapy is thought to represent
a promising strategy for treatment of GBM.4 Indeed, the
antivascular endothelial growth factor (VEGF) agent bev-
acizumab improves progression-free survival of GBM.5
However, antiangiogenic therapy for brain tumors poten-
tially induces neuronal cytotoxicity, invasiveness of the tumor
cells,6,7 and resistance to therapy,3e5,8,9 which diminish thestigative Pathology.
.beneﬁts of current antiangiogenic therapy for GBM. Thus, to
establish safe and efﬁcient therapies that have long-term
antietumor activity and fewer adverse effects, we need to
understand the comprehensive mechanisms that govern brain
tumor angiogenesis.
Most of the work in tumor angiogenesis has been focused
on identifying the genetic and chemical signals that control
neovascularization.3,10 Thus, most US Food and Drug
Administration (FDA)eapproved angiogenesis inhibitors
target soluble angiogenic factors such as VEGF.5,8,9,11 These
chemical signaling cascades are clearly necessary for tumor
Mammoto et algrowth and vascular development; however, the insoluble
extracellular matrix (ECM) and mechanical forces have
equally important roles in tumor angiogenesis and pro-
gression.12e19 Cell shape controls the growth of capillary
endothelial cells,20 and mechanical forces such as matrix
stiffness control cell migration, angiogenesis, tumor
progression, and metastasis, both in vitro and in vivo.15,21e23
Normal brain ECM is composed of hyaluronan, proteo-
glycans, and tenascin-C and is devoid of rigid ECM struc-
tures formed by ﬁbrillar collagens,24 whereas ECM in GBM
is associated with a large increase in components such as
collagens, laminin, and ﬁbronectin,25,26 primarily in the
basement membrane of the blood vessels, which suggests
that modifying these tumor-speciﬁc ECM components could
be a potentially promising strategy for treatment of brain
tumors.
Physical compaction is the process in which cells gather
and pack together, causing associated changes in cell shape
and size. Mesenchymal condensation, in which dispersed
mesenchymal cells are tightly packed together, results in
differentiation of these cells into speciﬁc tissue types that
occur during early development of various organs (eg, tooth,
cartilage, bone, muscle, tendon, kidney, and lung) in
mice.27,28 During the course of mesenchymal condensation,
cell shape is changed, cell size is decreased, and cell density
is increased, which results in changes in mechanical and
chemical signaling in the cells and dictates various cellular
behaviors such as proliferation, migration, and cell fate
determination that are critical for organ-speciﬁc morpho-
genesis. Physical compaction of the mesenchyme during
early organ development increases collagen expression and
governs subsequent organogenesis.29 In addition, changes in
cell shape control cell growth through the Rho signaling
pathway in capillary endothelial cells,20 and mechanical
forces elicited by ECM stiffness, which also change cell
shape and size, control angiogenesis and vascular func-
tion.22,30 Proliferating cancer cells in a conﬁned space
undergo compressive stress,16,31 and physically compacted
cancer cells exhibit aggressive phenotypes.32,33 For example,
rapidly growing mammary tumor cells in conﬁned spaces
become smaller and packed (ie, physically compacted),32
which affects tumor cell behavior and collagen VI expres-
sion.34 Therefore, in addition to soluble factors, mechanical
forces such as physical compaction of the cells and subse-
quent changes in expression and structure of collagen may
contribute to tumor angiogenesis and GBM progression.
However, the role of physical properties of the tumor
microenvironment on brain tumor angiogenesis and
progression has not been well elucidated.
The present study was initiated to examine whether tumor
cell compaction and associated changes in cell shape and
density control collagen and angiogenic factor expression
using in vitro experimental methods (ie, microcontact
printing system and mechanical compressor) (Supplemental
Figure S1). We have previously used these methods to
examine the effects of physical compaction in normal1294development,29 in which we could precisely change cell
size, shape, and density to mimic physical compaction
in vitro. We also altered collagen expression and structure
by changing the crosslinking ability of collagens and
examined whether it controls brain tumor angiogenesis and
tumor growth in vivo. Compaction of GBM cells changes
collagen expression and structure, resulting in increased
VEGF expression in vitro. Inhibition of collagen cross-
linking attenuated the effects of physical compaction of
GBM cells on tumor angiogenesis and progression of GBM
in a mouse orthotopic brain tumor model. Because this
novel approach targets tumor-speciﬁc ECM structures, it
may lead to development of more stable and efﬁcient anti-




Antiecollagen IV, antiecollagen VI, antieKi-67, anti-
HIF2a, and antielysyl oxidase (LOX) polyclonal antibodies
were purchased from Abcam (Cambridge, MA); anti-CD31
monoclonal antibody from BD Biosciences (San Jose, CA);
anti-VEGFR2 polyclonal antibody from Cell Signaling
Technology, Inc. (Boston, MA); antieglyceraldehyde-3-
phosphate dehydrogenase (GAPDH), antiematrix metal-
loproteinase (MMP)e2, and antieMMP-9 antibodies from
Millipore Corp. (Billerica, MA); and antieb-actin antibody,
b-aminopropionitrile (BAPN), and D-penicillamine from
Sigma (St. Louis, MO). U87MG, U251, and LN229 human
glioblastoma cell lines (ATCC, Manassas, VA) were
cultured in minimum essential medium containing 10% fetal
bovine serum.35
Fabrication of Micropatterned Substrates
The microcontact printing method for producing glass
substrates containing micrometer-sized ECM islands has been
described previously.29,36 In brief, polydimethylsiloxane
(PDMS) stamps were cast, cured, and removed from
master templates, which were created using photolitho-
graphic methods. Stamps were coated with 50 mg/mL
ﬁbronectin for 1 hour and dried using compressed
nitrogen. Flat and thin PDMS substrates were prepared on
the cover glass and UV oxidized for 5 minutes (Ellsworth
Adhesives, Germantown, WI), stamped with ﬁbronectin,
blocked with Pluronic F108 (Sigma) for 2 hours, and
rinsed three times with PBS before plating various GBM
cells. The cells were cultured on the ﬁbronectin island at
low (0.2  105 cells/cm2) or high (2.4  105 cells/cm2)
plating density to recapitulate the physical compaction of
the tumor cells in vivo (Supplemental Figure S1). After
16 hours of culture, densities and projected cell areas of
the cells attached to the ECM islands were measured
under a phase contrast microscope.ajp.amjpathol.org - The American Journal of Pathology
Collagen Controls GBM ProgressionMechanical Compression of GBM Cell Pellets
We fabricated a mechanical compressor (base and piston)
using ﬂexible, gas-permeable PDMS elastomer in which cell
pellets can be mechanically compressed in a controlled way.
One PDMS membrane was sealed to the bottom of the base,
and the entire compressor rested on a ﬁne wire mesh for
support.29 The pellets of three GBM cell lines (106 cells per
pellet) treated separately were placed at the base of the
device. The PDMS piston was placed on top of the pellet,
and a 30-g metal weight was placed over the PDMS piston
to compress the pellet with constant pressure of 1 kPa for 16
to 24 hours of culture (Supplemental Figure S1).
Animal Experiments
All animal studies were reviewed and approved by the
Animal Care and Use Committee of Boston Children’s
Hospital. Homozygous athymic nude mice [NU(NCr)-
Foxn1nu, stock No. 490; Charles River Laboratories Inter-
national, Inc., Wilmington, MA) were used in the present
study. For stereotactic injection into the brain in the tumor
xenograft model,37 U87MG human glioblastoma cells were
trypsinized and resuspended in PBS. Nude mice were
anesthetized using 250 mg/kg avertin i.p. and placed on
a stereotactic frame (Stoelting Co., Wood Dale, IL). Mice
were immobilized using blunt ear bars, and a 1.0-cm
sagittal incision was made to expose the cranium. A hole
was bored 1.5 mm lateral and 2 mm anterior to the bregma
using an electric drill. GBM cells, 5  105, in 10 mL PBS
were loaded into a 25-mL syringe (Gastight; Hamilton Co.,
Reno, NV) with a 25-gauge blunt needle. The needle was
inserted 1.5 mm beneath the pial surface, and cells were
infused over 3 minutes. The needle was left in the infusion
site for an additional 2 minutes before removal. Tumor
angiogenesis and growth were evaluated at 12 days after
implantation.
Brain Tumor Morphometry
Murine brains were ﬁxedwith 4% paraformaldehyde solution
overnight at 4C and embedded in OCT compound.29 Serial
sections (20 mm thick) were cut and were analyzed via H&E
staining and immunohistochemistry (IHC).22,29 Morpho-
metric analysis was performed as described previously29
using ImageJ software version 1.46r (NIH, Bethesda, MD).
Biochemical and Molecular Biological Methods
LOX activity in the tumor homogenate was measured using
a LOX activity assay kit (ABD Bioquest, Inc., Sunnyvale,
CA) in which LOX substrate that releases hydrogen
peroxide was detected.15,30,38,39 Hydroxyproline in brain
tumor tissue or serum was measured using a hydroxyproline
assay kit (BioVision, Inc., Milpitas, CA).30,40 The levels
of human VEGF in the tumor cell lysate from threeThe American Journal of Pathology - ajp.amjpathol.orgglioblastoma cell lines (U87MG, U251, and LN229) in vitro
and the levels of human VEGF and human basic ﬁbroblast
growth factor (bFGF) in brain tumor in vivo were measured
using an enzyme-linked immunosorbent assay (ELISA)
(R&D Systems, Inc., Minneapolis, MN). Immunoblotting of
collagen IV, collagen VI, LOX, MMP-2, MMP-9, b-actin,
and GAPDH from the tumor cell lysate of the same three
GBM cell lines in vitro or brain tumor in vivo was per-
formed as described.22 Quantitative RT-PCR (RT-qPCR)
was performed using the Quantitect SYBR Green RT-PCR
kit (Qiagen NV, Venlo, The Netherlands) using the ABI
7300 real-time PCR system (Applied Biosystems, Inc.,
Foster City, CA).22 b2-Microglobulin and cyclophilin were
used as controls for overall cDNA content. The primers used
are given in Table 1.
Statistical Analysis
Error bars (SEM) and P values were determined from the
results of at least three independent experiments. The unpaired
t-test was used for analysis of statistical signiﬁcance.
Results
Cell Compaction Increases Expression of Collagens and
VEGF in GBM Cells
Physical compaction of tissues and subsequent changes in cell
shape and ECM deposition result in cell fate switching in vitro
and in vivo bymodulating speciﬁc gene expression.29 Physical
compaction of rapidly growing cancer cells in conﬁned spaces
also has a key role in tumor progression in vivo.32,34 Because
angiogenesis is an important step in tumor growth and
metastasis in GBM3,4 and is controlled by mechanical
forces,22,41 we ﬁrst examined whether tumor cell compaction
regulates expression of angiogenic factors and ECMs in
U87MG, U251, and LN229 GBM cell lines. To explore
whether changes in cell shape, size, and density by physical
cell compaction contribute to angiogenic factor expression, we
precisely controlled cell size and density using micro-
engineered adhesive islands29,36 coated with the ECM protein
ﬁbronectin, which is present in glioblastomas in vivo42
(Supplemental Figure S1). U87MG, U251, and LN229 cells
cultured for 16 hours on large circular 500-mm diameter
ﬁbronectin islands at a high plating density of 2.4 105 cells/
cm2 induced cell compaction and resulted in reduction in cell
size by 34%, 26%, and 36%, respectively, compared with cells
plated at a low plating density of 0.2  105 cells/cm2 in 2D
culture (Figure 1A). Expression of the angiogenic factor
VEGF in U87MG, U251, or LN229 cells was 2.9-, 3.1-, and
2.5-fold higher, respectively, for mRNA (Figure 1B), and 5.9-,
5.9-, and 4.3-fold higher, respectively, for protein levels
compared with cells plated at the low plating density
(Figure 1C). Collagen VI is speciﬁcally up-regulated and
deposited around individual mesenchymal cells within the
condensed mesenchyme during the early stage of tooth1295
Table 1 RT-qPCR Primers Sequences
Primer Forward Reverse
Human VEGF 50-TCGAGTACATCTTCAAGCCATCCTGTGTGC-30 50-CCTATGTGCTGGCCTTGGTGAGGTTTGAT-30
Human collagen IV 50-GGACTACCTGGAACAAAAGGG-30 50-GCCAAGTATCTCACCTGGATCA-30
Human collagen VI 50-ACAGTGACGAGGTGGAGATCA-30 50-GATAGCGCAGTCGGTGTAGG-30
Human LOX 50-CGGCGGAGGAAAACTGTCT-30 50-TCGGCTGGGTAAGAAATCTG-30
Human b2-microglobulin 50-GAATGGAGAGAGAATTGAAAAAGTGGAGCA-30 50-CAATCCAAATGCGGCATCTTCAAAC-30
Mouse collagen IV 50-CTGGCACAAAAGGGACGAG-30 50-ACGTGGCCGAGAATTTCACC-30
Mouse collagen VI 50-CTGCTGCTACAAGCCTGCT-30 50-CCCCATAAGGTTTCAGCCTCA-30
Mouse cyclophilin 50-CAGACGCCACTGTCGCTTT-30 50-TGTCTTTGGAACTTTGTCTGCAA-30
Mammoto et aldevelopment.29 Collagen VI expression is also increased
during mammary tumor progression.34 Thus, we examined
whether expression of collagen VI is also changed in glio-
blastoma cells in a cell densityedependent manner. Consistent
with previous ﬁndings in early tooth development,29 the
collagen VI mRNA levels in U87MG, U251, or LN229 cells
plated at high density were 2-, 1.5-, and 1.9-fold higher,1296respectively (Figure 1D). Collagen IV, one of the major forms
identiﬁed in brain tumor samples, and collagen crosslinker
LOX mRNA levels were also signiﬁcantly higher than those
plated at low density (Figure 1D). Immunoblotting and IHC
conﬁrmed that protein expression of collagens and LOX was
higher in glioblastoma cells plated at high density (Figure 1E
and Supplemental Figure S2). The cell densityedependentFigure 1 Cell density and mechanical
compression control collagen, lysyl oxidase (LOX)
and angiogenic factor expression in glioblastoma
cells in vitro. AeD: Glioblastoma cell lines U87MG,
U251, and LN229 were cultured for 16 hours on
microfabricated, 500-mm diameter ﬁbronectin
islands at low (0.2 105 cells/cm2) or high (2.4
105 cells/cm2) plating cell density in vitro. A: Phase
contrast micrographs. Scale bar Z 100 mm. Pro-
jected cell areas were measured under each
condition. B: VEGF mRNA levels. C: VEGF protein
levels in three glioblastoma cell lines cultured for
16 hours on microfabricated circular ﬁbronectin
islands at low or high density. D: mRNA levels of
collagen (Col) VI and IV and LOX. E: Representative
immunoblots show Col VI and IV, LOX, and GAPDH
protein levels in three glioblastoma cell lines
cultured for 16 hours on microfabricated circular
ﬁbronectin islands at low (L) or high (H) density.
Quantitative results of protein levels of Col VI and
IV and LOX were normalized to GAPDH protein
levels. mRNA levels of VEGF (F) and Col VI and IV
and LOX (G) in control versus compressed (comp.)
glioblastoma cells. *P < 0.05. Data are given as
means  SEM of at least three independent
experiments.
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Figure 2 Lysyl oxidase (LOX) controls glio-
blastoma growth in mouse brain. A: Representative
micrographs show brain tumors (arrows) growing
in mouse brain for 12 days after implantation of
U87MG cells. Treatment with b-aminopropionitrile
(BAPN) was started on the day of tumor implan-
tation. Light micrographs show brain tumor
growing in brains of control and BAPN-treated
mice. Quantitation shows size of tumor growing
in mouse brain (n Z 8). B: Representative
micrographs show brain tumors (arrows) growing
in mouse brain for 12 days after implantation of
U87MG cells. Treatment with BAPN was started 4
days after tumor implantation. Light micrographs
show brain tumor growing in brains of control or
BAPN-treated mice. Quantitation shows size of
tumor growing in mouse brain (nZ 8). C: Relative
LOX activity was measured in mouse brain tumors
treated with BAPN (n Z 8). D: Micrographs show
representative brain tumors harvested 12 days
after implantation of U87MG cells. Weight of brain
tumors treated with BAPN was measured (n Z 8).
*P < 0.05. Error bars represent SEM. Scale bar Z
5 mm (A and B, top panels); 1 mm (A and B,
bottom panels).
Collagen Controls GBM Progressionincrease in the levels of collagens, LOX, and VEGF observed
in the three GBM cell lines U87MG, U251, and LN229
suggests that cell compactionedependent changes in GBM
cell size and density control collagen expression and VEGF
production in vitro. To further explore whether physical
compaction of the cells induces angiogenic factor expression
in three dimensional culture, we made pellets of the glioblas-
toma cell lines and mechanically compressed them between
two blocks of PDMS polymer for 16 hours using constant
pressure of 1 kPa 29 (Supplemental Figure S1). VEGF
expression was up-regulated in the compressed glioblastoma
cell pellets compared with unloaded controls (Figure 1F).
Mechanical compression of the glioblastoma cell pellets also
up-regulated mRNA expression of collagens VI and IV and
LOX (Figure 1G), conﬁrming that mechanical forces that
cause cell compaction change collagen and angiogenic factor
expression in vitro.
LOX Controls Glioblastoma Progression in Vivo
Breast cancer progression is accompanied by changing
ECM structure and mechanics that are controlled by theThe American Journal of Pathology - ajp.amjpathol.orgactivity of the ECM crosslinking enzyme LOX.15,19,43
Inhibition of LOX activity represses the malignant
behavior of mammary epithelial cells, therefore impeding
cancer progression in vivo.15,19,43 Because ECM structure
and stiffness control angiogenesis in vivo22 and LOX
expression is increased in a cell compactionedependent
manner in GBM cells in vitro (Figure 1, D, E, and G), we
next examined whether inhibition of LOX activity represses
brain tumor growth and angiogenesis in vivo using an
orthotopic mouse brain tumor model in which U87MG cells
were stereotactically injected into the mouse brain cortex.37
To manipulate LOX activity in the brain, mice were given 3
mg/kg LOX inhibitor BAPN in drinking water15,30,44
beginning on the day of tumor implantation. BAPN pre-
vents crosslinking of collagens,45,46 major tumor ECM
components in GBM,25,26 and has been extensively used
in vitro and in vivo to evaluate the role of LOX in cell
proliferation,47 embryonic development,48 and tumor cell
reversion15 and invasion.49 Consistent with previous reports
of breast cancer,15,43,49 BAPN decreased brain tumor size
by 65% compared with brain tumors in untreated mice at 12
days after implantation (Figure 2A). We also evaluated the1297
Figure 3 Lysyl oxidase (LOX) controls collagen
expression in brain tumor. A: Levels of hydroxy-
proline were measured in brain tumors and serum
in mice treated with b-aminopropionitrile (BAPN)
(nZ 7). BAPN treatment was started 4 days after
tumor implantation. B: mRNA levels of collagens
(Col) IV and VI were measured in mouse brain
tumors treated with BAPN (n Z 7). Immunoblots
show protein levels of Col IV and VI and GAPDH in
mouse brain tumors treated with BAPN (BA).
Quantitation of protein levels of Col IV and VI was
normalized to GAPDH protein levels. C: Immuno-
ﬂuorescence micrographs show Col VI expression
and distribution in brain tumors in control (Ct) and
BAPN-treated mice. Col VI density was measured in
brain tumors in control versus BAPN-treated mice
(n Z 8). D: H&E staining of brain tumors in
control and BAPN-treated mice. E: Cell area and
cell density were measured in brain tumors in
control and BAPN-treated mice (n Z 8). *P <
0.05. Error bars represent SEM. Scale barZ 75 mm
(C and D).
Mammoto et aleffects of BAPN on established orthotopic brain tumors
in vivo by starting BAPN therapy 4 days after tumor
implantation. BAPN therapy decreased LOX activity in
tumors by 42% as measured using a LOX activity assay
(Figure 2C).15,44 It decreased tumor size by 72%, and
weight by 58%, compared with tumors in untreated animals
(Figure 2, B and D), which suggests that LOX inhibition
could be a potential strategy for treatment of GBM.
Because cell compaction, a prominent feature of tumors,
increased collagen expression in GBM cells in vitro
(Figure 1), we next examined whether BAPN alters collagen
expression and/or turnover by measuring the amount of 4-
hydroxyproline, a common nonproteinogenic amino acid
found in collagen and elastin in mammals. Hydroxyproline
in tissue hydrolysates is a direct measure of the amount of
collagen present in the tissue,40 and conditions that increase
collagen turnover can result in elevated serum hydrox-
yproline concentration.50 BAPN decreased the hydrox-
yproline level in the tumor by 27%, whereas it increased
serum concentration by 28% (Figure 3A), which suggests
that BAPN decreased collagen volume in the tumor and
increased the rate of turnover in addition to altering collagen
crosslinking ability. When we examined the expression of
collagen IV and VI, the major types of collagen in brain
tumors, BAPN did not signiﬁcantly decrease collagen IV1298expression but decreased collagen VI expression by 75% and
93%, respectively, at mRNA and protein levels (Figure 3B).
We further conﬁrmed the results using IHC. In control
untreated tumors, thick and tortuous collagen VI ﬁbers were
distributed over the tumors, whereas in BAPN-treated
tumors, collagen VI ﬁbers were thinner and the density was
lower by 67% (Figure 3C). Cell size was 60% larger, and
cell density was lower by 45% in BAPN-treated tumors
compared with untreated control tumors (Figure 3, D and E),
suggesting that inhibition of collagen crosslinking may feed
back and further suppress tumor cell compaction. In addition,
blood vessels detected by the vessel markers CD31 and
VEGFR2 in the implanted tumors were thinner, and density
was lower by 66% in BAPN-treated tumors compared with
control untreated tumors (Figure 4A). VEGF mRNA and
protein levels as measured by RT-qPCR and ELISA were
also decreased, by 49% and 37%, respectively, in BAPN-
treated tumors (Figure 4B). Tumor cell proliferation detec-
ted via Ki-67 staining conﬁrmed that BAPN decreased tumor
cell proliferation by 65% (Figure 4C). These ﬁndings suggest
that inhibition of LOX activity disrupts collagen expression
and structure and hence represses tumor angiogenesis and
growth.
It has become clear that the FDA-approved anti-VEGF
therapy can promote inﬁltration or invasion of GBMajp.amjpathol.org - The American Journal of Pathology
Figure 4 Lysyl oxidase (LOX) controls angio-
genesis in brain tumors. A: Immunoﬂuorescence
micrographs show CD31-stained blood vessels
(green) and VEGFR2 expression (magenta) in brain
tumors from control (Ct) or b-aminopropionitrile
(BAPN)-treated mice. BAPN treatment started 4
days after tumor implantation. Vessel density and
VEGFR2 expression (Exp) were measured in brain
tumors from control and BAPN-treated mice (n Z
8). B: mRNA levels of VEGF were measured in
mouse brain tumors treated with BAPN (n Z 8).
Protein levels of VEGF was measured via ELISA in
mouse brain tumors treated with BAPN (nZ 7). C:
Immunoﬂuorescence micrographs show Ki-67
(green) and DAPI (blue) staining in brain tumors
from control or BAPN-treated mice. Percent Ki-67e
positive cells was measured in brain tumors from
control and BAPN-treated mice (n Z 8). D: Light
micrographs show tumors growing in brains of
control and BAPN-treated mice. Arrowheads show
necrotic areas. Immunoﬂuorescence micrographs
show staining of invasion-related proteins MMP-2
and MMP-9 and hypoxia-related protein HIF2a
in brain tumors from control and BAPN-treated
mice. E: Representative immunoblots show MMP-2,
MMP-9, and b-actin protein levels in brain tumors
from control or BAPN (BA)etreated mice. Quanti-
tation of protein levels of MMP-2 and MMP-9 was
normalized to b-actin protein levels (n Z 6). *P <
0.05. Data are given as means  SEM. Scale bars:
75 mm [A, C, and D (MMP2, MMP9, and HIF2a
columns)]; 0.5 mm (D, H&E column).
Collagen Controls GBM Progressioncells.6,51 Therefore, we also examined the effect of BAPN
on the invasive phenotype of the tumors. Control untreated
tumors had undeﬁned edges, and multiple satellite tumors
were present around the principal mass, whereas BAPN-
treated tumors had well-delineated margins and no satel-
lite tumors (Figure 4D). We also examined the levels of
invasion-related proteins such as MMP-2 and MMP-9 in
control and BAPN-treated tumors. IHC (Figure 4D) and
immunoblotting (Figure 4E) revealed that the levels of
MMP-2 and MMP-9 in the edge of the tumors were lower
in BAPN-treated tumors than in control untreated tumors.
Control untreated tumors also demonstrated a number of
necrotic regions, whereas BAPN-treated tumors exhibited
few necrotic regions. Because necrotic regions are poten-
tially caused by hypoxia, we also evaluated the hypoxic
phenotype via IHC using the hypoxia marker HIF-2a in
a mouse orthotopic tumor model. Consistent with the results
for necrosis, the levels of HIF2a in the tumors were lower
in BAPN-treated tumors than in control untreated tumorsThe American Journal of Pathology - ajp.amjpathol.org(Figure 4D). These results suggest that although LOX
inhibition by BAPN decreases the levels of VEGF in tumors,
it does not promote glioma invasion and necrosis.
D-Penicillamine Inhibits GBM Progression in Vivo
Our ﬁndings suggest that collagen structure and remodeling
have an important role in brain tumor progression, and the
LOX inhibitor BAPN seems to inhibit brain tumor growth
and angiogenesis (Figure 2, 3, and 4). However, because of
its nonspeciﬁc chemical effects and toxicity,52 BAPN has not
been approved for clinical use. LOX is a copper-dependent
enzyme, and copper is essential for the functional activity
of this enzyme, including extracellular processing of colla-
gens and elastin.53 D-Penicillamine, an FDA-approved agent
used to treat intracerebral copper overload in Wilson’s
disease,54 inhibits glioma growth and tumor angiogenesis in
experimental animal models.55 Consistent with a previous
report, whenwe treated orthotopically implanted glioblastoma1299
Mammoto et altumors with D-penicillamine, beginning 4 days after implan-
tation, tumor size was signiﬁcantly smaller in treated mice
than in untreated control mice (Figure 5, A and B), and
LOX activity was reduced by 41% in tumors treated with1300D-penicillamine (Figure 5C). When we examined collagen
expression and degradation using the hydroxyproline assay,
D-penicillamine decreased the tumor hydroxyproline level by
22%, whereas it increased serum hydroxyproline concentra-
tion by 30% (Figure 5D), which suggests that D-penicillamine
also decreased collagen expression and increased its turnover,
as observed in BAPN-treated tumors (Figure 3A). In addition,
RT-qPCR and immunoblotting revealed that D-penicillamine
decreased collagen VI mRNA and protein expression by 47%
and 61%, respectively, but did not change collagen IV levels
signiﬁcantly (Figure 5E). IHC also conﬁrmed that D-penicil-
lamine decreased collagenVI density and thickness by 42% in
treated tumors compared with untreated tumors (Figure 5F),
which suggests that D-penicillamine modulates collagen
structure in the tumor primarily by altering collagen VI
crosslinking ability and expression levels. Insofar as tumor
angiogenesis, D-penicillamine decreased tumor VEGFmRNA
and protein levels by 26% and 25%, respectively (Figure 6A),
and blood vessel density by 26% (Figure 6B). D-Penicillamine
diminished tumor cell proliferation by57%, as detected viaKi-
67 (Figure 6C). These results suggest that collagen expression
and structure modulated by LOX have key roles in tumor
angiogenesis andprogression inGBMinwhich tumor cells are
compacted.We also examined the effect of D-penicillamine on
the invasive phenotype of the tumors. Similar to the BAPN-
treated tumors (Figure 4D), D-penicillamine-treated tumors
exhibited well-delineated margins without satellite tumors
(Figure 6D), and the levels ofMMP-2 andMMP-9were lower
in tumors treated using D-penicillamine than in control
untreated tumors (Figure 6, D and E). In addition, compared
with untreated tumors, those treated with D-penicillamine
exhibited a decreased necrotic and HIF2a-positive hypoxic
phenotype (Figure 6D). Furthermore, cell size was 30% larger
and cell density was 45% lower in D-penicillamineetreated
tumors compared with untreated control tumors (Figure 6F),
similar to the tumors treated with BAPN, which suggests that
D-penicillamineeinduced inhibition of collagen crosslinking
also seems to feed back and suppress tumor cell compaction.Figure 5 D-Penicillamine controls collagen expression and structure in
mouse brain tumors. A: Representative micrographs show tumors (arrows)
growing in brains of control (Ct) or D-penicillamineetreated mice. D-Peni-
cillamine treatment was started 4 days after tumor implantation. H&E
staining of brain tumors from control or D-penicillamineetreated mice. B:
Size of tumors growing in brains of control or D-penicillamine (peni)etreated
mice (n Z 8). C: Lysyl oxidase (LOX) activity of tumors growing in brains
of control or D-penicillamineetreated mice (n Z 8). D: Hydroxyproline
levels were measured in brain tumors and serum from control or
D-penicillamineetreated mice (nZ 7). E: Left: mRNA levels of collagen (Col)
IV and VI in brain tumors from control or D-penicillamineetreated mice (nZ
8). Right: Quantitation of protein levels of Col IV and VI was normalized to
GADPH protein levels (n Z 6). Representative immunoblots show protein
levels of Col IV, Col VI, and GAPDH in brain tumors from control and
D-penicillamineetreated mice. F: Immunoﬂuorescence micrographs show Col
VI structure and distribution in brain tumors from control or D-penicillaminee
treated mice. Col VI density in brain tumors was measured from control or
D-penicillamineetreated mice (nZ 8). *P< 0.05. Data are given as means
SEM. Scale bars: 5 mm (A, top panels); 1 mm (A, bottom panels); 75 mm (F).
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Figure 6 D-Penicillamine controls angiogen-
esis and tumor growth in mouse brain tumors. A:
VEGF mRNA (n Z 8) and protein (n Z 8) levels
were measured in brain tumors from control (Ct) or
D-penicillamine (peni)etreated mice. B: Immuno-
ﬂuorescence micrographs show CD31-stained
blood vessels in brain tumors from control or
D-penicillamineetreated mice. Vessel density was
measured in brain tumors from control or D-peni-
cillamineetreated mice (n Z 8). C: Immunoﬂuo-
rescence micrographs show Ki-67 (green) and DAPI
(blue) staining in brain tumors from control or
D-penicillamineetreated mice. Percent Ki-67e
positive cells was measured in brain tumors from
control or D-Penicillamineetreated mice (n Z 8).
D: Light micrographs (H&E stained) show brain
tumor growing in control or D-penicillaminee
treated mice. Arrowheads show necrotic areas.
Immunoﬂuorescence micrographs show staining of
invasion-related proteins MMP-2 and MMP-9 and
hypoxia-related protein HIF2a in brain tumors
from control or D-penicillamineetreated mice. E:
Immunoblots show MMP-2, MMP-9, and b-actin
protein levels in brain tumors from control or
D-penicillamineetreated mice. Quantitation of
protein levels of MMP-2 and MMP-9 was normalized
to b-actin protein levels (nZ 6). F: H&E staining of
brain tumors in control or D-penicillamineetreated
mice. Cell area and cell density were measured in
brain tumors from control or D-penicillaminee
treated mice (n Z 8). *P < 0.05. Error bars
represent SEM. Scale bars: 75 mm [B, C, D (MMP2,
MMP9, and HIF2a columns), and F]; 0.5 mm (D,
H&E column).
Collagen Controls GBM ProgressionDiscussion
In addition to genetic and chemical signals that control tumor
angiogenesis,3,4,10 insoluble ECM and mechanical forces
have equally important roles in tumor progression.12e19 We
found that growth of glioblastoma cells in conﬁned spaces
induces physical compaction of the cells and increases
collagen expression and changes in its structure, which
results in induction of tumor angiogenesis and GBM
progression in murine orthotopic brain tumors. Inhibition ofThe American Journal of Pathology - ajp.amjpathol.orgcollagen crosslinking and expression using BAPN or D-
penicillamine suppressed angiogenesis and GBM progres-
sion in the mouse model. Inhibition of collagen crosslinking
and expression also seems to feed back to suppress tumor cell
compaction and further inhibit angiogenesis and GBM
progression. In contrast to normal brain, in which the ECM is
composed primarily of hyaluronan, proteoglycans, and
tenascin-C but lacks much collagen,24 GBM tumors consist
of ﬁbrillar collagens, primarily in the basement membrane of
the blood vessels.25,26 Thus, targeting the process of collagen1301
Mammoto et alremodeling, which is speciﬁc for tumors in the brain, could
be a novel and efﬁcient strategy for treatment of GBM.
Multicellular drug resistance is associated with cellular
compaction in ovarian cancer cells and mammary tumor
cells.33,56,57 Tumor cell compaction is also involved in
resistance to radiotherapy in colon cancer.58 Thus, modiﬁers
of tumor cell compaction or subsequent collagen remodeling
could also reduce drug resistance in various other cancers.
During early tooth development, physically compacted
mesenchymal cells synthesize and deposit collagens and
induce subsequent organ development, which is controlled
by two distinct growth factors, semaphorin and ﬁbroblast
growth factor 8.29 Although GBM cell compaction increased
expression of collagens, their crosslinker LOX, and the
angiogenic factor VEGF, the mechanism by which tumor cell
compaction and up-regulation of these proangiogenic mole-
cules occurs remains unknown.
Consistent with other reports of mammary tumor
progression,15 the LOX inhibitor BAPN inhibited LOX
activity in the tumor, disrupted collagen structure, and
repressed GBM progression in a mouse brain tumor model.
LOX can change the expression or activities of various
chemical factors that may directly inﬂuence tumor angio-
genesis (eg, transforming growth factor-b, platelet-derived
growth factor-BB, and VEGF)59e61 or alter ECM structure
in multiple ways and hence contribute to GBM progression.
However, LOX inhibitors such as BAPN and D-penicilla-
mine did not inhibit endothelial cell differentiation when
analyzed using an endothelial cell tube formation assay
in vitro (data not shown), which suggests that the direct
physical effects of LOX on ECM remodeling may have an
essential role in tumor cell behavior and angiogenesis
in vivo.
LOX inhibition may render collagen more susceptible to
degradation.62 Indeed, when we measured the amount of
hydroxyproline in brain tumor tissue and serum, BAPN and
D-penicillamine decreased the levels of hydroxyproline in
tumor but increased the concentrations in serum, which
suggests that in addition to changing the structure of ECM,
BAPN and D-penicillamine decreased the amount of
collagen and increased the rate of turnover. However,
treatment with BAPN or D-penicillamine clearly changed
collagen structure, ﬁber density, and thickness in the tumors,
and therefore these treatments seem to affect tumor growth,
at least in part, by inhibiting collagen crosslinking ability.
Changes in ECM structure may also feed back to alter LOX
activity or expression, ECM expression levels, ECM turn-
over rate, and intracellular signaling activity, all of which
remodel tumor ECM structure in different ways in
a spatiotemporal manner and modify angiogenesis and
vascular function (permeability), which can further alter
tumor cell behavior. Furthermore, inhibition of LOX
activity seems to feed back to inhibit tumor cell compaction
and suppress angiogenesis and tumor growth. Thus,
complex feedback systems control ECM structure and
tumor growth.1302Although cell compaction increased both collagen IV and
VI levels in vitro, LOX inhibition decreased collagen VI
levels but not collagen IV levels in vivo. This may be
because our in vitro studies used brain tumor cells cultured
on top of one type of ECM component, whereas the whole
tumor microenvironment contains various cell types grown
in three-dimensional ECMs composed of many kinds of
insoluble ECM components and bound growth factors.
Tumor epithelial, stromal, or endothelial cells may secrete
soluble factors and ECM proteins differently in response to
changes in cell compaction and LOX manipulation.
Although the FDA-approved anti-VEGF therapy seems to
be effective in normalizing abnormal tumor vasculature,
leading to an enhanced response to radiation and chemo-
therapy, anti-VEGF therapy can promote expression of
proangiogenic and proinvasive factors and eventually
stimulate glioma inﬁltration or invasion and become resis-
tant to the therapy.6,51 For example, hepatocyte growth
factoreMet signaling in GBM cells, which is negatively
regulated by VEGF-A,63 enhances growth and invasion of
the cells in response to bevacizumab treatment.64 Conse-
quently, FDA-approved VEGF-A neutralizing antibody
bevacizumab (Avastin) does not improve overall survival in
patients with GBM.65 Although manipulation of LOX
activity using BAPN or D-penicillamine decreased VEGF
levels in the tumor, unlike anti-VEGF therapy, it did not
promote tumor cell invasion and/or the hypoxic or necrotic
phenotype in a murine orthotopic tumor model, which
suggests that ECM-targeting strategies may attenuate the
adverse effects of current antiangiogenic therapy. Given that
angiogenesis is in part controlled by ECM structure and
mechanics and that tumor cell compaction is involved in
drug resistance during cancer therapy, modifying ECM
structure associated with tumor cell compaction in combi-
nation with conventional antiangiogenic therapy (such as
bevacizumab) and/or radiotherapy could improve response,
decrease toxic adverse effects, and prevent resistance by
changing the tumor microenvironment.
We used D-penicillamine as a more clinically relevant
approach to inhibit LOX activity and disrupt collagen
structure. In addition to VEGF, copper has important roles
in angiogenesis66 and is involved in tumor angiogenesis by
changing the levels of FGFs; the release of bFGF is
inhibited by chelating copper in tumors.67,68 bFGF increases
over time in patients with recurrent glioblastoma during
treatment with VEGFR inhibitor or anti-VEGF therapy.6,69
However, when we analyzed whether the levels of bFGF
are also altered in D-penicillamineetreated implanted
tumors using RT-qPCR and ELISA, mRNA and protein
levels of bFGF were not changed in D-penicillaminee
treated tumors (data not shown). The copper chelating
effects of D-penicillamine that decrease bFGF levels and
anti-VEGF effects that increase bFGF levels may leave
bFGF levels unchanged in the tumor. Our results suggest
that D-penicillamine decreased collagen expression and
disrupted collagen structure in tumors and inhibited brainajp.amjpathol.org - The American Journal of Pathology
Collagen Controls GBM Progressiontumor growth in an experimental murine orthotopic tumor
model. However, this drug has not improved survival in
patients with GBM.55 Modiﬁcation of the treatment strategy
such as time course, dosages, route of administration, or
combination with other collagen modiﬁers may improve the
efﬁciency of the approach.55,70,71
In summary, tumor cell compaction changes collagen
structure and expression and controls VEGF-mediated
tumor angiogenesis and GBM growth. Our ﬁndings may
lead to new and better understanding of the pathogenesis of
GBM, which will open opportunities for development of
new therapeutic interventions for GBM and other hyper-
vascular brain tumors.
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